Oncology Clinical Trials in Salt Lake City, UT

As of September 2026, 197 paid clinical trials are recruiting for Oncology in Salt Lake City, Utah. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

198 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in Salt Lake City, UT.

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Drug: Teclistamab

Sites in Salt Lake City +34 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07518186·Phase 3·Recruiting·Listed Apr 2026

Apply to this trial

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for Pancreatic Cancer

Drug: daraxonrasib

Sites in Salt Lake City +12 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07491445·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

for PROC

Sites in Salt Lake City +11 more locations

Sponsor: Whitehawk Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07470853·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

for Myelodysplastic Syndrome

Sites in Salt Lake City +24 more locations

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07422480·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

Sites in Salt Lake City +27 more locations

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

Drug: Giredestrant

Sites in Salt Lake City +25 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

for Lymphoma, Non-Hodgkin

Sites in Salt Lake City +22 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07101328·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for Metastatic Solid Tumor

Drug: LY4052031

Sites in Salt Lake City, West Valley City +19 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06465069·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

for Advanced/Metastatic Solid Tumors

Sites in Salt Lake City +25 more locations

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT03526835·Phase 1, Phase 2·Recruiting·Listed May 2018

Apply to this trial

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

for Advanced Solid Tumor

Drug: AI-081

Sites in Salt Lake City +20 more locations

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT06635785·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

for Colorectal Neoplasms

Sites in Salt Lake City, West Valley City +19 more locations

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT06131840·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

for Metastatic Prostate Cancer

Sites in Salt Lake City +19 more locations

Sponsor: ORIC Pharmaceuticals

Sex: Male·Age: 18+

Code: NCT05413421·Phase 1·Recruiting·Listed Jun 2022

Apply to this trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for Malignant Neoplasm

Sites in Salt Lake City +15 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT06941272·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

for Metastatic Solid Tumor

Sites in Salt Lake City, West Valley City +16 more locations

Sponsor: Coherus Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06657144·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for B-cell Acute Lymphoblastic Leukemia

Sites in Salt Lake City +16 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 25

Code: NCT06395103·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

for Advanced Solid Tumor

Sites in Salt Lake City +10 more locations

Sponsor: Aulos Bioscience, Inc.

Sex: All·Age: 18+

Code: NCT05267626·Phase 1, Phase 2·Recruiting·Listed Mar 2022

Apply to this trial

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

for Glioblastoma

Sites in Salt Lake City +15 more locations

Sponsor: CarThera

Sex: All·Age: 18+

Code: NCT05902169·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

for Solid Tumor

Sites in Salt Lake City +19 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04939610·Phase 1, Phase 2·Recruiting·Listed Jun 2021

Apply to this trial

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

for Metastatic Melanoma

Drug: Lifileucel

Sites in Salt Lake City +17 more locations

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05727904·Phase 3·Recruiting·Listed Feb 2023

Apply to this trial

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

for SST2-positive Neuroendocrine Neoplasms

Sites in Salt Lake City +22 more locations

Sponsor: Crinetics Pharmaceuticals Inc.

Sex: All·Age: 18+

Code: NCT07129252·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

for Ovarian Cancer

Sites in Salt Lake City +12 more locations

Sponsor: NextCure, Inc.

Sex: All·Age: 18+

Code: NCT06774963·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in Salt Lake City +13 more locations

Sponsor: Debiopharm International SA

Sex: All·Age: 12+

Code: NCT04855656·Phase 1·Recruiting·Listed Apr 2021

Apply to this trial

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for Urothelial Carcinoma

Sites in Salt Lake City +8 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05562830·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

for Non-Small Cell Lung Cancer

Sites in Salt Lake City +15 more locations

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06917079·Phase 1·Recruiting·Listed Apr 2025

Apply to this trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

for Non-small Cell Lung Cancer (NSCLC)

Sites in Salt Lake City +20 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05379985·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

for Urothelial Carcinoma Bladder

Sites in Salt Lake City +11 more locations

Sponsor: Aktis Oncology, Inc.

Sex: All·Age: 18+

Code: NCT07020117·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for PDAC

Sites in Salt Lake City +17 more locations

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06922591·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Sites in Salt Lake City +21 more locations

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06343402·Phase 1·Recruiting·Listed Apr 2024

Apply to this trial

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

for Solid Tumor

Sites in Salt Lake City +14 more locations

Sponsor: NiKang Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06586957·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for Pancreatic Ductal Adenocarcinoma

Sites in Salt Lake City +12 more locations

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07020221·Phase 1, Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

QTX3034 in Patients With KRAS G12D Mutation

for Solid Tumors

Sites in Salt Lake City +13 more locations

Sponsor: Quanta Therapeutics

Sex: All·Age: 18+

Code: NCT06227377·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

for Non Small Cell Lung Cancer

Sites in Salt Lake City +14 more locations

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06810544·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for Advanced or Metastatic Solid Tumors

Sites in Salt Lake City +13 more locations

Sponsor: 858 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06395519·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

for Head and Neck Carcinoma

Sites in Salt Lake City +13 more locations

Sponsor: VM Oncology, LLC

Sex: All·Age: 18 - 80

Code: NCT03556228·Phase 1, Phase 2·Recruiting·Listed Jun 2018

Apply to this trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

Sites in Salt Lake City +22 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

for Colorectal Cancer

Sites in Salt Lake City +19 more locations

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT05234177·Recruiting·Listed Feb 2022

Apply to this trial

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

for Relapsed Multiple Myeloma

Sites in Salt Lake City +11 more locations

Sponsor: Opna Bio LLC

Sex: All·Age: 18+

Code: NCT06433947·Phase 1·Recruiting·Listed May 2024

Apply to this trial

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

for Low-grade Glioma

Sites in Salt Lake City +11 more locations

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 6 Months - 25

Code: NCT04775485·Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

for Malignant Neoplasm

Sites in Salt Lake City +7 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT07630974·Phase 1, Phase 2·Recruiting·Listed Jun 2026

Apply to this trial

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

for Bladder Cancer

Sites in Salt Lake City +3 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07232602·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

Conditions in Oncology (Salt Lake City, UT)

Solid tumor· 31 Non-small cell lung cancer (NSCLC)· 27 Breast cancer· 24 Multiple myeloma· 15 Cancer (any)· 15 Acute myeloid leukemia (AML)· 14 Pancreatic cancer· 12 Ovarian cancer· 12 Non-Hodgkin lymphoma· 12 Diffuse large B-cell lymphoma (DLBCL)· 10 Colorectal cancer· 9 Endometrial cancer· 9 Head and neck cancer· 9 Lung cancer· 8 Prostate cancer· 7 Myelodysplastic syndromes (MDS)· 7 Myelofibrosis· 7 Hematologic malignancy· 7 Melanoma· 7 Metastatic prostate cancer· 6 Metastatic breast cancer· 5 Gastric cancer· 5 Bladder cancer· 5 Glioblastoma· 5 Mantle cell lymphoma· 5 Neuroblastoma· 5 Neuroendocrine tumors· 5 Triple-negative breast cancer· 4 Esophageal cancer· 4 Chronic lymphocytic leukemia (CLL)· 4 Acute lymphoblastic leukemia· 4 Leukemia (other)· 4 Marginal zone lymphoma· 4 Cervical cancer· 3 Fallopian tube cancer· 3 Gynecologic cancer· 3 Follicular lymphoma· 3 Small lymphocytic lymphoma· 3 HER2-negative breast cancer· 2 Gastroesophageal junction cancer· 2 Biliary tract cancer· 2 Kidney cancer· 2 Glioma· 2 Brain cancer· 2 Brain metastases· 2 Myeloproliferative neoplasm· 2 Hodgkin lymphoma· 2 Osteosarcoma· 2 Ewing sarcoma· 2 Rhabdomyosarcoma· 2 HER2-positive breast cancer· 1 Small cell lung cancer· 1 Metastatic colorectal cancer· 1 Colon cancer· 1 Gastrointestinal cancer· 1 Burkitt lymphoma· 1 Skin cancer· 1 Thyroid cancer· 1 Sarcoma· 1 Pediatric cancer· 1 Mesothelioma· 1